You are here

Gossamer Bio

Gossamer Bio and Chiesi Group to collaborate in therapy for lung condition

Reuters

Mon, 05/6/24 - 11:35 am

The Chiesi Group

pulmonary arterial hypertension

Biopharma Layoff Tracker 2023: Rain Oncology, Takeda, PTC and more cut staff

BioSpace

Wed, 05/31/23 - 11:15 am

PTC Therapeutics

Urovant Sciences

Bristol Myers Squibb

ADC Therapeutics

Big Pharma layoffs: BMS, Roche and Takeda axe hundreds of jobs

Medical Marketing and Media

Mon, 05/15/23 - 10:04 am

Bristol Myers Squibb

Gossamer cuts loose 25% of its staff, ties future to phase 3 trial of tarnished Merck rival

Fierce Biotech

Wed, 05/10/23 - 10:10 am

Gossamer Bio announces FDA has placed a partial clinical hold on all trials of GB5121 in response to serious adverse events

Investing.com

Mon, 04/3/23 - 10:59 pm

Gossamer pauses enrollment of lymphoma med, citing risk-benefit profile

Fierce Biotech

Sun, 03/19/23 - 01:43 pm

clinical trials

Gossamer could put pressure on Merck

EP Vantage

Fri, 11/11/22 - 10:26 am

United Therapeutics

Phase 2 deja vu for gossamer bio after ulcerative colitis med flops

Fierce Biotech

Mon, 04/25/22 - 10:37 pm

ulcerative colitis

clinical trials

Gossamer Bio seeking out partners for failed DP2 antagonist, says it has 'viable path forward'

Fierce Biotech

Sun, 02/28/21 - 10:08 pm

eosinophilic asthma

Despite Phase 2 Failure, Gossamer Bio Sees a Path for Drug in Asthma

Xconomy

Tue, 10/13/20 - 09:49 pm

clinical trials

eosinophilic asthma

Biotech companies raise cash as coronavirus updates lift stocks

BioPharma Dive

Tue, 05/19/20 - 11:24 pm

Moderna Therapeutics

Turning Point Therapeutics

Krystal Biotech

Clovis Oncology

A Look at 5 Big and Interesting Biotech IPOs for 2019

BioSpace

Fri, 12/20/19 - 12:36 pm

Adaptive Biotechnologies

Novartis' asthma drug fails in phase 3, raising doubts about Gossamer's prospects

Fierce Biotech

Tue, 10/22/19 - 10:28 am

clinical trials

BioSpace's List of February 2019 Life Science IPOs

BioSpace

Mon, 02/11/19 - 08:22 pm

Shockwave Medical

Harpoon Therapeutics

Hoth Therapeutics

Gossamer Bio Adds $276M in Second Biotech “Unicorn” IPO of 2019

Xconomy

Thu, 02/7/19 - 11:34 pm

With US government shutdown over, Gossamer reverts to traditional IPO plan

Endpoints

Thu, 01/31/19 - 10:13 am

government shutdown

Gosssamer Bio to Use 20 Day Rule for $230 Million IPO

Wed, 01/23/19 - 09:14 pm

Gossamer sets fixed share price for $230M IPO to sidestep shutdown

BioCentury

Wed, 01/23/19 - 08:14 pm

government shutdown

Gossamer Bio Plans to Raise $264.5 Million with IPO

BioSpace

Wed, 12/26/18 - 04:34 pm

Four Healthcare Startups Raised Over $130 Million Last Month

Forbes

Tue, 08/7/18 - 11:46 pm

Compass Therapeutics